What We're Reading
Industry reads hand-picked by our editors
Sep 21, 2018
-
Drugmakers’ Free Services Spur Government Scrutiny
The Wall Street Journal
-
Sloan Kettering's Cozy Deal With Start-Up Ignites a New Uproar
The New York Times
-
FDA may crack down on clinical trial reporting
BioCentury
-
Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial
STAT
Sep 20, 2018
-
Gilead faces doubts on Wall Street a year after $12 billion deal
Bloomberg
-
What is Tilray? Why the Canadian cannabis company is worth more than American Airlines
Vox
-
In the battle for life sciences companies, one state shows up behind enemy lines
Stat
-
Despite red flags at surgery centers, overseers award gold seals
Kaiser Health News
Sep 19, 2018
-
Black Patients Miss Out On Promising Cancer Drugs
ProPublica
-
AstraZeneca plots China robot offensive to counter price cuts
Reuters
-
Why Your DNA Is Still Uncharted Territory
The New York Times
-
Novartis nears gene therapy confirmation
Evaluate
Sep 18, 2018
-
Trump promised a rush of repatriated cash, but company responses are modest
The Wall Street Journal
-
Novartis links bonuses to ethics in bid to rebuild reputation
Reuters
-
A Nobel laureate asks what makes a ‘disordered mind’
The New York Times
Sep 17, 2018
-
The Worst Is Over for Generic-Drug Stocks
The Wall Street Journal
-
For elderly women with breast cancer, surgery may not be the best option
The New York Times
-
Few safeguards for foster kids on psych drugs
Associated Press
Sep 14, 2018
-
Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
The New York Times
-
Regeneron plans to add 1,500 in East Greenbush
Albany Times Union
-
Roche steps up efficiency drive to take sting out of biosimilars
Reuters
-
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
Kaiser Health News